Levels of cholesteryl esters and other lipids in the plasma of patients with end-stage renal failure

Annals of Saudi Medicine

Volumn 21, Issue 5-6, 2001, Pages 283-286

  Gillett, Michael P T ^a   Obineche, Enyioma N ^a   Lakhani, Mohammed S ^a   Abdulle, Abdishakur M ^a   Amirlak, Iradj ^a   Al Rukhaimi, Mona ^a   Suleiman, Mustafa N ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Cholesteryl esters; Chronic renal failure; Lecithin cholesterol acyltransferase; Plasma lipids

Indexed keywords

CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CALCULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPOPROTEINEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

EID: 0035741248     PISSN: 02564947     EISSN: None     Source Type: Journal    
DOI: 10.5144/0256-4947.2001.283     Document Type: Article

References (34)

1. Accelerated atherosclerosis in prolonged maintenance haemodialysis
2. Long-term cardiac morbidity and mortality during dialysis therapy
3. Atherogenesis and cardiac death: Are they related to dialysis procedure and biocompatibility?
4. Outcome and risk factors of ischemic heart disease in chronic uraemia
5. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study
6. Controlling the epidemic of cardiovascular disease in chronic renal disease. What do we know? what do we need to learn? where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease
7. Lipopheresis in the nephrotic syndrome
8. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients
9. Importance of hyperlipidaemia and therapy in renal patients
10. Effect of lipid reduction on the progression of renal disease: A meta-analysis
11. Lipid lowering in end-stage renal disease
12. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease
13. Role of hyperlipidemia in progressive renal disease: Focus on diabetic nephropathy
14. Lipoprotein glomerulopathy: Significance of lipoprotein and ultrastructural features
15. Atherogenic lipoproteins, oxidative stress, and cell death
16. Risk factors predicting chronic rejection of renal allograft
17. Hyperlipidaemia in renal transplantation: Risk factor for long-term graft outcome
18. Role of circulating lipid abnormalities in chronic renal allograft rejection
19. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia
20. Lecithincholesterol acyltransferase activity, HDL-cholesterol and apolipoprotein A in serum of patients undergoing chronic haemodialysis
21. Plasma lecithin-cholesterol acyltransferase activities in uraemic patients
22. Lecithin-cholesterol acyltransferase activity in dialyzed and undialyzed chronic uremic patients
23. Plasma lipoproteins and lecithin-cholesterol acyltransferase distribution in patients on dialysis
24. Decreased plasma lecithin-cholesterol acyltransfer and associated changes in plasma and red cell lipids in uraemia
25. Plasma concentrations of lysolecithin and other phospholipids in the healthy population and in men suffering from atherosclerotic disease
26. Cholesterol-esterifying enzymes-lecithin-cholesterol acyltransferase and acylcoenzyme A: Cholesterol acyltransferase
27. Lipoprotein metabolism in renal failure
28. Low-density lipoprotein subclass patterns and risk of myocardial infarction
29. Atherogenic lipoprotein phenotype in end-stage renal failure: Origin and extent of small low-density lipoprotein formation
30. Physiological role of lecithin-cholesterol acyltransferase
31. Effect of treatment with simvastatin on serum cholestryl ester transfer in patients on dialysis
32. Plasma cholesterol metabolism in end-stage renal disease. Differences between treatment by haemodialysis or peritoneal dialysis
33. Reduction of intermediate lipoprotein by pravastatin in hemoand peritoneal dialysis patients
34. Inhibition of lecithin-cholesterol acyltransferase following intravenous administration of heparin in man